福泰制药Vertex Pharmaceuticals Inc. (VRTX) 2006年10-K年度报告「NASDAQ」.pdf

1、FORM 10-K VERTEX PHARMACEUTICALS INC/MA(Annual Report)Filed 3/1/2007 For Period Ending 12/31/2006Address130 WAVERLY STREETCAMBRIDGE,Massachusetts 02139-4242Telephone616-577-6000 CIK0000875320IndustryBiotechnology&DrugsSectorHealthcareFiscal Year12/31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

2、WASHINGTON,D.C.20549 FORM 10-K Commission file number 000-19319 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter)Registrants telephone number,including area code(617)444-6100 Securities registered pursuant to Section 12(b)of the Exchange Act:Securities regist

3、ered pursuant to Section 12(g)of the Exchange Act:None Indicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No?Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d)of the E

4、xchange Act.Yes?No Indicate by check mark whether the registrant:(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months(or for such shorter period that the registrant was required to file such reports),and(2)has been

5、subject to such filing requirements for the past 90 days.Yes No?Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein,and will not be contained,to the best of the registrants knowledge,in definitive proxy or information statements in

6、corporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.?Indicate by check mark whether the registrant is a large accelerated filer,an accelerated filer,or a non-accelerated filer.See definition of“accelerated filer and large accelerated filer”in Rule 12b-2 of the Ex